Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 12:40 pm ET.

Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time following the event.

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 12:40 pm ET.

A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When is Protara Therapeutics (TARA) presenting at the Oppenheimer Healthcare Conference 2025?

Protara Therapeutics will present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, at 12:40 pm ET.

How can investors watch Protara Therapeutics' (TARA) Oppenheimer Conference presentation?

Investors can watch the presentation through a live webcast available on Protara's investor relations website at https://ir.protaratx.com in the Events and Presentations section.

Will Protara Therapeutics' (TARA) Oppenheimer Conference presentation be available for replay?

Yes, the webcast will be archived and available for a time following the presentation on Protara's website.

What type of presentation will Protara Therapeutics (TARA) give at the Oppenheimer Conference 2025?

Protara Therapeutics will participate in a virtual fireside chat format presentation at the conference.